Sustained Same-Store NOI Growth
Total portfolio same-store NOI grew 12.1% in Q1 2026, marking the ninth consecutive quarter of double-digit same-store NOI growth.
Trilogy (ISHC) Outperformance
Trilogy delivered same-store NOI growth of 14.5% with same-store occupancy averaging 91.2% (up ~220 bps year-over-year). Same-store revenue grew 6.9% and same-store NOI margins eclipsed 20% (first time since COVID). Quality mix improved to 75.5% of resident days (up ~60 bps YoY).
SHOP Segment Strength
SHOP same-store NOI increased 19.7% with same-store occupancy at 88.6% (up ~255 bps YoY) and same-store NOI margin expanded ~215 bps to 20.6%.
Strong Earnings Growth (NFFO)
Reported normalized funds from operations (NFFO) of $0.50 per diluted share in Q1 2026, a 31.6% increase from $0.38 in Q1 2025.
Raised 2026 Guidance
Raised full-year same-store NOI growth guidance to a range of 9%–12% and increased full-year NFFO per share guidance (midpoint up $0.04) to reflect an expected ~20% NFFO per share growth over 2025. Segment-level same-store NOI guidance: Trilogy 11%–15%, SHOP 15%–19%, outpatient medical 0%–2%, triple-net 2%–3%.
Active, Accretive Acquisition Program
Year-to-date closed acquisitions of $249.2 million (approximately $162.8 million in Q1), subsequent quarter-end closings of ~$86.4 million, and 2025 acquisitions of $950 million contributing to earnings. Management emphasized accretive deployment and selective, operator-first underwriting.
Large Awarded Pipeline
Pipeline of over $650 million in awarded SHOP deals (management expects the majority to close by quarter-end with the remainder in Q3), plus an in-process development pipeline of ~$173.9 million in expected cost (≈$52.4 million funded).
Improved Balance Sheet and Liquidity
Net debt to annualized EBITDA improved to 3.0x as of 03/31/2026 (down from 3.4x at year-end 2025). Increased unsecured revolver capacity from $600 million to $800 million (maturity extended to April 2030) with $0 outstanding, and ATM/forward sale agreements in place representing significant potential gross proceeds (examples: ~8.1 million shares for $412.7 million; unsettled forward agreements representing ~ $527.4 million).